Bristol Myers Squibb Research at ESMO Congress 2022 Highlights Depth of Development Program Across Early- and Late-Stages of Cancer
05.09.2022 - Bristol Myers Squibb (NYSE: BMY) today announced the presentation of scientific research across several solid tumors showcasing the breadth of the Company’s oncology development program at the European Society for Medical Oncology (ESMO) Congress ...
Source: wallstreet-online.de